The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes

• Published in: Blood advances 2018-10, Vol.2 (20), p.2658-2671
• Main Authors: McNamara, Caroline J., Panzarella, Tony, Kennedy, James A., Arruda, Andrea, Claudio, Jaime O., Daher-Reyes, Georgina, Ho, Jenny, Siddiq, Nancy, Devlin, Rebecca, Tsui, Hubert, Su, Jie, Stockley, Tracy, Sukhai, Mahadeo, Kanwar, Nisha, Chan, Steven, Maze, Dawn, Schimmer, Aaron, Schuh, Andre, Sibai, Hassan, Viswabandya, Auro, Yee, Karen, Minden, Mark D., Kamel-Reid, Suzanne, Gupta, Vikas
• Format: Article
• Language: English
• Subjects: Myeloid Neoplasia
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2018021469

There is a paucity of data regarding the impact of mutations on outcomes in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs). Moreover, it is unknown whether mutational status affects survival, as seen in chronic-phase MPNs. Therefore, we performed a retrospective analysis of all patients treated at our institution with AP/BP MPNs (N = 122; AP = 14; BP = 108) to comprehensively describe the mutational profile and correlate with clinical outcomes. Targeted sequencing with a 54-gene panel was performed. Forty-four patients were treated with intensive therapy, 27 with nonintensive therapy, and 51 with best supportive care (BSC). The most common mutation was JAK2V617F, occurring in 55% of subjects; CALR was found in 13% of patients and MPL in 6%. Thirty-two (26%) patients were triple negative. Other frequently mutated genes were ASXL1 (30%), TET2 (25%), SRSF2 (22%), RUNX1 (20%), and TP53 (17%). Mutations in 1, 2, 3, and ≥4 genes were seen in 15%, 13%, 25%, and 46% of patients, respectively. There was no difference in survival between patients treated with intensive vs nonintensive therapy, and the benefit of intensive therapy was limited to patients who were able to undergo transplantation. TP53 was the only individual mutation to correlate with shorter overall survival (hazard ratio, 1.89; P = .03). In the multivariate analysis, mutated TP53, ≥4 mutations, low albumin, increased peripheral blood blasts, ≥3 cytogenetic abnormalities, and BSC were associated with shorter survival. In conclusion, mutational data enhance the understanding of patients with AP/BP MPN who are likely to benefit from current therapeutic options. •Mutant TP53 and ≥4 mutations predict dismal outcomes with current therapeutic options in patients with accelerated/blast phase of MPNs.•The benefit of intensive therapy is only seen in patients who are able to undergo transplant. [Display omitted]